Related Experiment Video
Updated: Aug 18, 2026
Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
Published on: June 9, 2022
HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen
Meital Gal-Tanamy1, Romy Zemel, Yevgeny Berdichevsky
1Department of Molecular Microbiology and Biotechnology, The George S. Wise Faculty of Life Sciences, Green Building, Room 202, Tel-Aviv University, Ramat Aviv, Israel.
Insights
Researchers developed a novel bacterial screen to find Hepatitis C virus (HCV) NS3 protease inhibitors. This screen identified single-chain antibodies that effectively inhibit HCV NS3 activity and viral replication.
Area of Science:
- Virology and Molecular Biology
- Drug Discovery and Development
- Immunology
Background:
- Hepatitis C virus (HCV) infection poses a significant global health challenge, leading to chronic hepatitis, liver cirrhosis, and primary liver cancer.
- Existing antiviral therapies for HCV often exhibit treatment failures, necessitating the development of more effective, specific, and less toxic therapeutic options.
- The HCV NS3 protease is a critical viral enzyme and a primary target for antiviral drug development due to its essential role in viral replication.
Purpose of the Study:
- To develop and validate a novel bacterial genetic screening system for identifying inhibitors of the Hepatitis C virus (HCV) NS3 protease.
- To isolate and characterize single-chain variable fragment (scFv) antibodies that inhibit NS3 protease activity.
- To assess the efficacy of identified scFv inhibitors in cell-based assays targeting HCV replication.
Main Methods:
- A bacterial genetic screen was engineered by co-expressing a reporter gene (beta-galactosidase), the HCV NS3 protease, and fusion-stabilized single-chain antibodies (scFvs) in Escherichia coli.
- The reporter system utilized an engineered beta-galactosidase enzyme cleavable by NS3 protease; NS3 activity resulted in a loss of enzyme function (transparent colonies), while inhibition restored function (blue colonies).
- scFv inhibitors were isolated from an immunized mouse spleen library, and their binding specificity and inhibitory activity were confirmed using ELISA and in vitro catalysis assays, respectively.
Main Results:
- The developed bacterial screen successfully identified scFvs that specifically bind to and inhibit the catalytic activity of the HCV NS3 protease.
- Isolated scFv inhibitors demonstrated potent inhibition of NS3 protease in vitro and, when expressed as intracellular antibodies (intrabodies) in mammalian cells, reduced NS3-mediated cell proliferation.
- The genetic screen proved effective for isolating antibody-based inhibitors and is adaptable for identifying inhibitors from other molecular sources.
Conclusions:
- A novel and effective bacterial genetic screen has been established for the discovery of HCV NS3 protease inhibitors.
- The screen facilitated the isolation of specific single-chain antibody inhibitors (scFvs) with demonstrated antiviral activity against HCV.
- This platform holds promise for the broader identification of novel antiviral agents targeting essential viral enzymes.
Abstract:
Hepatitis C virus (HCV) infection is a major world-wide health problem causing chronic hepatitis, liver cirrhosis and primary liver cancer. The high frequency of treatment failure points to the need for more specific, less toxic and more active antiviral therapies for HCV. The HCV NS3 is currently regarded as a prime target for anti-viral drugs, thus specific inhibitors of its activity are of utmost importance. Here, we report the development of a novel bacterial genetic screen for inhibitors of NS3 catalysis and its application for the isolation of single-chain antibody-inhibitors. Our screen is based on the concerted co-expression of a reporter gene, of recombinant NS3 protease and of fusion-stabilized single-chain antibodies (scFvs) in Escherichia coli. The reporter system had been constructed by inserting a short peptide corresponding to the NS5A/B cleavage site of NS3 into a permissive site of the enzyme beta-galactosidase. The resulting engineered lacZ gene, coding for an NS3-cleavable beta-galactosidase, is carried on a low copy plasmid that also carried the NS3 protease-coding sequence. The resultant beta-galactosidase enzyme is active, conferring a Lac+ phenotype (blue colonies on indicator 5-bromo-4-chloro-3-indolyl beta-D-galactoside (X-gal) plates), while induction of NS3 expression results in loss of beta-galactosidase activity (transparent colonies on X-gal plates). The identification of inhibitors, as shown here by isolating NS3-inhibiting single-chain antibodies, expressed from a compatible high copy number plasmid, is based on the appearance of blue colonies (NS3 inhibited) on the background of colorless colonies (NS3 active). Our source of inhibitory scFvs was an scFv library that we prepared from spleens of NS3-immunized mice and subjected to limited affinity selection. Once isolated, the inhibitors were validated as genuine and specific NS3 binders by an enzyme-linked immunosorbent assay and as bone fide NS3 serine protease inhibitors by an in vitro catalysis assay. We further show that upon expression as cytoplasmic intracellular antibodies (intrabodies) in NS3-expressing mammalian cells, three of the scFvs inhibit NS3-mediated cell proliferation. Although applied here for the isolation of antibody-based inhibitors, our genetic screen should be applicable for the identification of candidate inhibitors from other sources.
